Skip to content
Products & Services · Total Revenues

Opdualag — Total Revenues

Bristol-Myers Squibb Opdualag — Total Revenues decreased by 15.7% to $295M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.1%, from $252M to $295M. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2020
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates strong market adoption and successful clinical positioning of the drug, while a decrease may signal increased competition or loss of market share in the immuno-oncology space.

Detailed definition

This metric represents the total global net sales generated from the commercialization of Opdualag, a fixed-dose combina...

Peer comparison

Comparable to revenue metrics for specific high-growth specialty pharmaceutical products or blockbusters in the oncology portfolios of peer biopharmaceutical companies.

Metric ID: bmy_segment_opdualag_total_revenues

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0$0$0$6M$58M$84M$104M$117M$154M$166M$190M$206M$235M$233M$254M$252M$284M$299M$350M$295M
QoQ Change+866.7%+44.8%+23.8%+12.5%+31.6%+7.8%+14.5%+8.4%+14.1%-0.9%+9.0%-0.8%+12.7%+5.3%+17.1%-15.7%
YoY Change>999%+165.5%+97.6%+82.7%+76.1%+52.6%+40.4%+33.7%+22.3%+20.9%+28.3%+37.8%+17.1%
Range$0$350M
Avg YoY Growth+194.2%
Median YoY Growth+40.4%

Frequently Asked Questions

What is Bristol-Myers Squibb's opdualag — total revenues?
Bristol-Myers Squibb (BMY) reported opdualag — total revenues of $295M in Q1 2026.
How has Bristol-Myers Squibb's opdualag — total revenues changed year-over-year?
Bristol-Myers Squibb's opdualag — total revenues increased by 17.1% year-over-year, from $252M to $295M.
What does opdualag — total revenues mean?
The total revenue generated from sales of the oncology drug Opdualag.